Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance

Citius Pharmaceuticals IncTrade
Vanguard Sht-Term Inflation-Protected Sec Idx ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.67. Which is the better fit depends on your goals.

CTXRVTIP
Market Cap
$18.73M
Sector
Health
52-Week High
$1.82$50.75
52-Week Low
$0.48$49.39
Enterprise Value
$14.95M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

Vanguard Sht-Term Inflation-Protected Sec Idx ETF

VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.67, up 0.08% with a bullish technical signal. The ETF focuses on short-term Treasury Inflation-Protected Securities, offering inflation hedging. Recent news highlights institutional buying and inflation concerns, with a dividend declared for July 2026. Technical indicators show mixed signals but overall positive momentum.

Outlook: VTIP provides inflation protection amid rising prices, with potential returns around 3.8% based on current inflation. Risks include interest rate volatility and Fed policy uncertainty. It suits investors seeking low-duration, inflation-linked income, but may underperform if inflation subsides unexpectedly.

Returns comparison

Trailing returns across standard periods

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Vanguard Sht-Term Inflation-Protected Sec Idx ETF

The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.

Read more on VTIP